Having relaunched itself in 2018, Avid Bioservices says it is going from strength-to-strength in the contract manufacturing space and its strategy will continue with a new CEO. Avid Bioservices emerged from drug developer Peregrine Pharmaceuticals in January 2018 as a pureplay contract development and manufacturing organization (CDMO). “While we were a product development organization, we also had manufacturing facilities to support the manufacturing of our pipeline. While we were focused on developing products, we were also offering our services for…